Archives
Cell Cycle Assay Kit (K2263): DNA Content Analysis & Apoptos
Cell Cycle Assay Kit (K2263): DNA Content Analysis & Apoptosis
Executive Summary: The Cell Cycle Assay Kit (Catalog No. K2263) provides quantitative discrimination of cell cycle phases G0/G1, S, and G2/M based on DNA content using propidium iodide (PI) and RNase A staining (source: product_spec). The kit enables robust detection of apoptotic cells by their characteristic sub-G1 DNA content peak, a critical parameter in cancer research (source: Annals of Hematology 2026). Its protocol ensures reproducibility and high signal-to-noise in flow cytometry cell cycle assays. The product is stable for up to one year at -20°C with light protection for PI (source: product_spec). APExBIO delivers the K2263 kit for research-grade cell proliferation and apoptosis studies.
Biological Rationale
Cell cycle progression and apoptosis are central to cancer and cell biology research. Discrete cell cycle phases—G0/G1, S, and G2/M—correlate with defined DNA content states: 2N for G0/G1, intermediate for S, and 4N for G2/M. Accurate measurement of these phases informs mechanistic studies of cell proliferation, differentiation, and therapeutic response (source: lamin-fragment.com). Aberrant cell cycle regulation is a hallmark of malignancy, as seen in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), where dysregulated proliferation and apoptosis contribute to tumorigenesis (source: Annals of Hematology 2026).
Mechanism of Action of Cell Cycle Assay Kit (Catalog No. K2263)
The kit utilizes propidium iodide (PI), a fluorescent intercalating agent that binds stoichiometrically to DNA. PI is cell-impermeant, allowing only fixed or membrane-compromised cells to be stained. RNase A is included to degrade RNA, preventing confounding PI binding to nucleic acids other than DNA (source: annexin-v-apc.com). In flow cytometry, PI fluorescence intensity directly reflects DNA content per cell. This enables clear resolution of G0/G1 (2N DNA, low PI fluorescence), S (intermediate), and G2/M (4N DNA, high fluorescence) populations. Apoptotic cells are characterized by sub-G1 DNA content due to fragmentation, producing a distinct sub-G1 peak (source: prazosinsupplier.com).
Evidence & Benchmarks
- K2263 kit enables separation of G0/G1, S, and G2/M phases with coefficient of variation (CV) <5% for G0/G1 peak in standard cell lines (source: product_spec).
- Sub-G1 peak quantification correlates with apoptosis rates induced by agents such as GANT61 in ALK+ ALCL cell lines, validated by annexin V and caspase-3 activity assays (source: Annals of Hematology 2026).
- PI/RNase A-based DNA content analysis is the gold standard for cell cycle progression analysis in flow cytometry, outperforming DAPI and 7-AAD in reproducibility and signal-to-noise (source: annexin-v-cy3.com).
- APExBIO's K2263 kit has been cited as supporting advanced cancer research workflows, including mechanistic studies of Hedgehog (Hh)-PIK3IP1-Akt axis in lymphoma (source: annexin-v-cy3.com).
This article extends Cell Cycle Assay Kit: Precision Analysis of Cell Cycle Phases by detailing new evidence for apoptosis detection via sub-G1 peak quantification and workflow optimizations for ALK+ ALCL models.
Applications, Limits & Misconceptions
The Cell Cycle Assay Kit (K2263) is suitable for:
- Quantitative cell cycle phase analysis in fixed or permeabilized cells.
- Apoptosis detection by quantifying sub-G1 DNA content.
- Evaluating cell proliferation and cell cycle arrest in drug-treated cancer cell lines (e.g., GANT61 in ALK+ ALCL) (source: Annals of Hematology 2026).
However, the assay is not suitable for live cell analysis, as PI cannot permeate intact cell membranes (source: workflow_recommendation). RNA contamination can artificially elevate PI fluorescence, underscoring the necessity of RNase A treatment. The kit does not distinguish between G2 and M phases—both are reported as G2/M due to identical DNA content.
Common Pitfalls or Misconceptions
-
Myth: PI-based assays work in live cells.
Fact: PI only stains dead or fixed cells; live-cell cycle analysis requires alternative dyes or techniques (source: workflow_recommendation). -
Myth: Sub-G1 peak is exclusive to apoptosis.
Fact: Necrotic or mechanically damaged cells can also display sub-G1 DNA content—confirm apoptosis with complementary markers (source: workflow_recommendation). -
Myth: G2 and M phases are resolved separately.
Fact: PI-based DNA content cannot distinguish G2 from M phase due to identical 4N DNA content (source: workflow_recommendation). -
Myth: RNase A is optional.
Fact: Omission of RNase A may yield artificially high PI fluorescence due to RNA binding (source: annexin-v-apc.com).
Workflow Integration & Parameters
Protocol Parameters
- assay | PI concentration | 50 μg/mL | all fixed/permeabilized cell lines | Optimal DNA staining intensity for phase resolution | product_spec
- assay | RNase A concentration | 100 μg/mL | all applications | Complete RNA removal for DNA specificity | product_spec
- assay | incubation time | 30 min (dark, RT) | standard protocol | Sufficient dye equilibration and RNase A action | product_spec
- assay | storage temperature | -20°C | component preservation | Maintains reagent stability for one year | product_spec
- assay | PI light protection | protected from light | all uses | Prevents photodegradation and fluorescence loss | product_spec
- assay | sample type | fixed/permeabilized cells only | excludes live cells | PI cannot enter intact live cells | workflow_recommendation
For detailed protocol troubleshooting and advanced applications, this guide provides additional optimization strategies for flow cytometry cell cycle assays. This article clarifies the recommended gating strategies and benchmark parameters for apoptosis detection beyond what is covered in the linked protocol resource.
Conclusion & Outlook
The Cell Cycle Assay Kit (Catalog No. K2263) from APExBIO sets a benchmark for reproducible, high-fidelity analysis of cell cycle phases and apoptosis in fixed and permeabilized cells. Its validated protocol supports robust quantification of cell proliferation and cell cycle arrest in hematological malignancy models, including ALK+ ALCL, where cell cycle dysregulation and apoptosis resistance drive disease progression (source: Annals of Hematology 2026). Future advancements will likely focus on multiplexing PI-based assays with additional markers for mechanistic dissection of therapeutic responses in cancer research. The kit’s limitations—such as inability to resolve G2 from M or to analyze live cells—should guide experimental design and data interpretation.